Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide

AIMS: To compare the pharmacokinetics (PK) of a single-dose of liraglutide in subjects with hepatic impairment. METHODS: This parallel group, open label trial involved four groups of six subjects with healthy, mild, moderate and severe hepatic impairment, respectively. Each subject received 0.75 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Flint, Anne, Nazzal, Khalil, Jagielski, Pawel, Hindsberger, Charlotte, Zdravkovic, Milan
Formato: Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2010
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997321/
https://www.ncbi.nlm.nih.gov/pubmed/21175436
http://dx.doi.org/10.1111/j.1365-2125.2010.03762.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997321/
https://www.ncbi.nlm.nih.gov/pubmed/21175436
http://dx.doi.org/10.1111/j.1365-2125.2010.03762.x

Ejemplares similares